Image

Factors Affecting Post-transplant Cyclophosphamide (PTCy) Efficacy

Recruiting
18 years of age
Both
Phase N/A

Powered by AI

Overview

This study will examine the influence of donor and recipient pharmacogenetics (PG), drug pharmacokinetics (PK), and T cell phenotypes and how it may permit a tailored dosing strategy to improve the therapeutic index of post-transplant cyclophosphamide (PTCy) and optimize the graft versus tumor effect, while minimizing acute and chronic graft versus host disease (GVHD).

Description

The primary objective of this single-arm, pilot study is to determine whether pharmacogenetics (PG) of Cy-related candidate genes from the recipients and/or donors (haploidentical and matched related donor HCTs only) germ-line DNA is associated with incidence and severity of acute and chronic GVHD. Secondary objectives include determining whether pharmacogenetics (PG) of Cy-related candidate genes from the recipients and/or donors (haploidentical and matched related donor HCTs only) germ-line DNA is associated with Cy (and metabolites) exposure and toxicities; quantifying Cy (and related metabolites) exposure measured as the area under the concentration time curve (AUC) from zero to 24 hours both before (day -6) and after transplant (day +3), and correlate exposure with incidence of acute and chronic GVHD, and Adverse Events of Special Interest (AESIs); and determining whether immune activation or polarization prior to or following Cy GVHD prophylaxis is associated with grade of acute or chronic GVHD grade and AESIs. Safety objects include evaluating Cy administered, adverse events of special interest (including deaths while on study therapy), selected laboratory parameters (including time to neutrophil recovery), and immunosuppressant concomitant medications administration. Initially, 20 participants (HCT recipients and their respective haploidentical or matched related donors) will be enrolled with a subsequent 100 additional subjects enrolled.

Eligibility

Inclusion Criteria

        Recipients and donors must meet all of the following applicable inclusion criteria to
        participate in this study:
          1. Informed consent and HIPAA authorization for release of personal health information
             signed by the subject.
          2. Age ≥ 18 years at the time of consent.
          3. Subject is scheduled as a recipient or respective donor (Donor consent/participation
             is not required for subjects undergoing matched unrelated donor HCT) for the following
             hematopoietic stem cell transplants (HCT) procedures using a non-myeloablative regimen
             at Levine Cancer Institute (LCI), and has been deemed a qualified candidate by his/her
             physician, per LCI medical standards: haplo-identical donor HCT, match related donor
             (MRD) HCT, matched unrelated donor (MUD) HCT.
          4. Recipient only: Planned post-transplant cyclophosphamide
          5. As determined by the enrolling physician, ability of the subject to understand and
             comply with study procedures for the entire length of the study
        Exclusion Criteria
        Subjects meeting any of the criteria below may not participate in the study:
          1. Recipient only (applies only to haplo-identical and MRD HCT recipients; not required
             for MUD HCT recipients): Does not have a respective donor who is willing to sign
             informed consent for participation in this study.
          2. Recipient only: Treatment with any investigational drug within 30 days prior to day -6
             of treatment
          3. Donor only (applies only to haplo-identical and MRD HCTs; donor participation is not
             required for MUD HCTs): Does not have a respective recipient who is willing to sign
             informed consent for participation in this study.

Study details

Leukemia, Not Otherwise Specified, Leukemia, Other

NCT03555851

Wake Forest University Health Sciences

25 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.